| Identification | More | [Name]
Betaxolol | [CAS]
63659-18-7 | [Synonyms]
BETAXOLOL
1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propan
2-propanol,1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)
Betaxolol Base
ZB-5
Betaxolols
(-1-(Isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol
1-[4-(2-(Cyclopropylmethyloxy)ethyl]-phenoxy]-3-[(1-methylethyl)amino]-2-propa nol
1-Isopropylamino-3-[4-(2-cyclopropylmethoxy-ethyl)phenoxy]-2-propanol
Betoptic S
1-[4-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(propan-2-ylamino)propan-2-ol
1-[4-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-(isopropylamino)-2-propanol
1-[4-[2-(Cyclopropylmethoxy)ethyl]phenoxy]-3-isopropylamino-2-propanol | [Molecular Formula]
C18H29NO3 | [MDL Number]
MFCD00242958 | [Molecular Weight]
307.43 | [MOL File]
63659-18-7.mol |
| Chemical Properties | Back Directory | [Appearance]
White Crystalline Solid | [Melting point ]
61-63°C | [Boiling point ]
448.0±40.0 °C(Predicted) | [density ]
1.067±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
pKa 9.21 (Uncertain) | [color ]
White | [Usage]
Cardioselective 1-adrenergic blocker. An antihypertensive; antiglaucoma | [CAS DataBase Reference]
63659-18-7(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Chemical Properties]
White Crystalline Solid | [Originator]
Kerlone,Carriere,France,1983 | [Uses]
Cardioselective 1-adrenergic blocker. An antihypertensive; antiglaucoma | [Uses]
Cardioselective β1-adrenergic blocker. An antihypertensive; antiglaucoma. | [Definition]
ChEBI: A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective
beta1-receptor blocker and is used in the treatment of glaucoma as well as hypertension, arrhythmias, and coronary heart disease. It is also used to reduce non-fatal cardiac events in patients with heart failure. | [Manufacturing Process]
(1) 1 g of sodium hydroxide pellets (0.025 mol) is added to a suspension of
3.8 g of 4-[2-(cyclopropylmethoxy)-ethyl]-phenol in 30 ml of water. When the
solution becomes homogenous, 2.3 ml of epichlorohydrin are added and the
mixture is stirred for 8 hours. It is then extracted with ether and the extract is
washed with water, dried over sodium sulfate and evaporated to dryness. The
compound is purified by passing it over a silica column. 2.4 g of 1-[4-[2-
(cyclopropylmethoxy)ethyl]-phenoxy]-2,3-epoxy-propane are thus obtained.
(2) 4.9 g of the preceding compound (0.02 mol) are condensed with 25 ml of
isopropylamine by contact for 8 hours at ambient temperature and then by
heating for 48 hours at the reflux temperature. After evaporation to dryness,
the compound obtained is crystallized from petroleum ether. 5 g (yield 80%)
of 2-[[4-(2-cyclopropylmethoxy)-ethyl]-phenoxy]-3-isopropylaminopropan-2-ol
are thus obtained, melting point 70° to 72°C.
The hydrochloride is prepared by dissolving the base in the minimum amount
of acetone and adding a solution of hydrochloric acid in ether until the pH is
acid. The hydrochloride which has precipitated is filtered off and is
recrystallized twice from acetone, melting point 116°C. | [Brand name]
Betoptic (Alcon); Kerlone (Sanofi Aventis). | [Therapeutic Function]
Beta-adrenergic blocker | [Biological Activity]
betaxolol is a cardioselective beta-adrenergic receptor blocking agent. betaxolol (5 mg/kg via i.p. injection) was administered at 24 and then 44 h following the final chronic cocaine administration. animals treated with betaxolol during cocaine withdrawal | [Veterinary Drugs and Treatments]
Betaxolol HCl is a specific Beta1 adrenergic blocking agent which
reduces aqueous humor production by decreasing cyclic-AMP
synthesis in the ciliary body. This drug is a suitable substitute for
timolol and because of its specific Beta1 activity, might be a first
choice Beta blocking agent for patients with concurrent respiratory
disease. Either levobunolol HCl or betaxolol HCl would be the first
choice Beta blocking agent in a feline patient with glaucoma and
asthma, although a topical carbonic anhydrates inhibitor should be
considered before a Beta blocking agent in this situation. Betaxolol
and the other Beta blockers should be used with caution in patients
with cardiac disease. | [Metabolism]
Absorption of an oral dose of betaxolol (Kerlone,
Betoptic) is almost complete. The drug is subject to a
slight first-pass effect such that the absolute bioavailability
of the drug is about 90%.Approximately 50% of
administered betaxolol binds to plasma proteins, and its
plasma half-life is about 20 hours; it is suitable for dosing
once per day.The primary route of elimination is by
liver metabolism, with only 15% of unchanged drug being
excreted. | [storage]
Store at -20°C |
|
|